| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Department of Biomedical Sciences and Pathobiology, Virginia-Maryland Regional College of Veterinary Medicine, Virginia Polytechnic Institute and State University and Edward Via College of Osteopathic Medicine, Blacksburg, VA 24060;
Medical Research Service, Ralph H. Johnson Veterans Administration Medical Center, Charleston, SC 29405, and Department of Medicine, Medical University of South Carolina, Charleston, SC 29425;
Department of Immunopathology, University of Miami Medical Center, Miami, FL 33124;
Aton Pharmaceuticals, Tarrytown, NY 10580;
¶ Memorial Sloan-Kettering Cancer Center, New York, NY 10021; and
|| Sections of Rheumatology and Clinical Immunology, Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC
Epigenetic regulation of gene expression is involved in the development of many diseases. Histone acetylation is a posttranslational modification of the nucleosomal histone tails that is regulated by the balance of histone deacetylases and histone acetyltransferases. Alterations in the balance of histone acetylation have been shown to cause aberrant expression of genes that are a hallmark of many diseases, including systemic lupus erythematosus. In this study, we determined whether suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor: 1) inhibits inflammatory mediator production in vitro and 2) modulates lupus progression in vivo. Mesangial cells isolated from 10-wk-old MRL/lpr mice were stimulated with LPS/IFN-
and incubated with SAHA. TNF-
, IL-6, NO, and inducible NO synthase expression were inhibited by SAHA. We then treated MRL/lpr mice with daily injections of SAHA from age 10 to 20 wk. The animals treated with SAHA had decreased spleen size and a concomitant decrease in CD4–CD8– (double-negative) T cells compared with controls. Serum autoantibody levels and glomerular IgG and C3 deposition in SAHA-treated mice were similar to controls. In contrast, proteinuria and pathologic renal disease were significantly inhibited in the mice receiving SAHA. These data indicate that SAHA blocks mesangial cell inflammatory mediator production in vitro and disease progression in vivo in MRL/lpr mice.
This article has been cited by other articles:
|
|
 |
|
  D. Bosisio, M. Vulcano, A. Del Prete, M. Sironi, V. Salvi, L. Salogni, E. Riboldi, F. Leoni, C. A. Dinarello, G. Girolomoni, et al. Blocking TH17-polarizing cytokines by histone deacetylase inhibitors in vitro and in vivo J. Leukoc. Biol., December 1, 2008; 84(6): 1540 - 1548. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Cao, C. Bao, E. Padalko, and C. J. Lowenstein Acetylation of mitogen-activated protein kinase phosphatase-1 inhibits Toll-like receptor signaling J. Exp. Med., June 9, 2008; 205(6): 1491 - 1503. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Glauben, A Batra, T Stroh, U Erben, I Fedke, H A Lehr, F Leoni, P Mascagni, C A Dinarello, M Zeitz, et al. Histone deacetylases: novel targets for prevention of colitis-associated cancer in mice Gut, May 1, 2008; 57(5): 613 - 622. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. T. Teachey, A. E. Seif, V. I. Brown, M. Bruno, R. M. Bunte, Y. J. Chang, J. K. Choi, J. D. Fish, J. Hall, G. S. Reid, et al. Targeting Notch signaling in autoimmune and lymphoproliferative disease Blood, January 15, 2008; 111(2): 705 - 714. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Wang, S. A. Mahmud, P. B. Bitterman, Y. Huo, and A. Slungaard Histone Deacetylase Inhibitors Suppress TF-{kappa}B-dependent Agonist-driven Tissue Factor Expression in Endothelial Cells and Monocytes J. Biol. Chem., September 28, 2007; 282(39): 28408 - 28418. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Nencioni, J. Beck, D. Werth, F. Grunebach, F. Patrone, A. Ballestrero, and P. Brossart Histone Deacetylase Inhibitors Affect Dendritic Cell Differentiation and Immunogenicity Clin. Cancer Res., July 1, 2007; 13(13): 3933 - 3941. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Forster, S. Gallinat, J. Jablonska, S. Weiss, H.-P. Elsasser, and W. Lutz p300 Protein Acetyltransferase Activity Suppresses Systemic Lupus Erythematosus-Like Autoimmune Disease in Mice J. Immunol., June 1, 2007; 178(11): 6941 - 6948. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Miwa, M. A. Maldonado, L. Zhou, K. Yamada, G. S. Gilkeson, R. A. Eisenberg, and W.-C. Song Decay-Accelerating Factor Ameliorates Systemic Autoimmune Disease in MRL/lpr Mice via Both Complement-Dependent and -Independent Mechanisms Am. J. Pathol., April 1, 2007; 170(4): 1258 - 1266. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Dong, Q-X Wang, C-Y Zhou, X-F Ma, and Y-C Zhang Activation of the STAT1 signalling pathway in lupus nephritis in MRL/lpr mice Lupus, February 1, 2007; 16(2): 101 - 109. [Abstract] [PDF]
|
|
|
|
|
|
J. L. Brogdon, Y. Xu, S. J. Szabo, S. An, F. Buxton, D. Cohen, and Q. Huang Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function Blood, February 1, 2007; 109(3): 1123 - 1130. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Ballestar, M. Esteller, and B. C. Richardson The epigenetic face of systemic lupus erythematosus. J. Immunol., June 15, 2006; 176(12): 7143 - 7147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Glauben, A. Batra, I. Fedke, M. Zeitz, H. A. Lehr, F. Leoni, P. Mascagni, G. Fantuzzi, C. A. Dinarello, and B. Siegmund Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J. Immunol., April 15, 2006; 176(8): 5015 - 5022. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
